Scholar Rock (NASDAQ: SRRK) announced Friday that it has removed Catalent Indiana as a fill-finish facility from its Biologics License Application for apitegromab, acting under guidance from the FDA.
The decision marks a notable development in the regulatory pathway for apitegromab, Scholar Rock’s lead investigational treatment targeting muscle mass and strength in spinal muscular atrophy patients.
Fill-finish manufacturing is a critical final stage of biologic drug production, involving the transfer of a drug substance into its final container before it reaches patients.
Regulatory agencies frequently scrutinize fill-finish facilities as part of the BLA review process, and any changes to designated sites can carry significant implications for approval timelines.
Scholar Rock confirmed the move was made under direct guidance from the FDA, suggesting the agency raised concerns or flagged the Indiana facility as part of its ongoing review.
Catalent, a contract development and manufacturing organization, has faced heightened regulatory scrutiny across several of its manufacturing sites in recent periods.
Novo Nordisk (NVO) has a financial stake in Catalent, which adds a layer of industry significance to the removal of the Indiana facility from Scholar Rock’s application.
The timing of the announcement, coming on a Friday morning, prompted a market reaction, with shares of Scholar Rock rising 2.26% while Novo Nordisk gained 1.30% on the session.
Investors and analysts will now be watching closely for any updated guidance from Scholar Rock on how this manufacturing change may affect the expected timeline for FDA action on the apitegromab BLA.
Scholar Rock has positioned apitegromab as a potentially transformative therapy, and any delays or complications in the regulatory process carry material consequences for the company’s commercial outlook and financial position.
The company has not yet indicated which alternative fill-finish facility will replace Catalent Indiana in the updated application, a detail that market participants will be eager to see clarified in the near term.
